Third Harmonic Bio Investor Relations Material
Latest events
Study Update
Third Harmonic Bio
Q1 2025
8 May, 2025
Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Third Harmonic Bio Inc
Access all reports
Third Harmonic Bio Inc., operating under the ticker THRD, is a clinical-stage biopharmaceutical company dedicated to developing therapies for inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. The company is actively working on novel treatments and focuses on KIT inhibition, a key regulatory mechanism in mast cell function, which plays a substantial role in inflammatory responses across these conditions. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
THRD
Country
🇺🇸 United States